AU660422B2 - Pathogen-specific CTL therapy - Google Patents

Pathogen-specific CTL therapy

Info

Publication number
AU660422B2
AU660422B2 AU87379/91A AU8737991A AU660422B2 AU 660422 B2 AU660422 B2 AU 660422B2 AU 87379/91 A AU87379/91 A AU 87379/91A AU 8737991 A AU8737991 A AU 8737991A AU 660422 B2 AU660422 B2 AU 660422B2
Authority
AU
Australia
Prior art keywords
pathogen
cells
ctl
infected
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU87379/91A
Other languages
English (en)
Other versions
AU8737991A (en
Inventor
Malcolm Gefter
Judy Lieberman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immulogic Pharmaceutical Corp
Tufts Medical Center Inc
Original Assignee
Immulogic Pharmaceutical Corp
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp, New England Medical Center Hospitals Inc filed Critical Immulogic Pharmaceutical Corp
Publication of AU8737991A publication Critical patent/AU8737991A/en
Application granted granted Critical
Publication of AU660422B2 publication Critical patent/AU660422B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU87379/91A 1990-09-06 1991-09-06 Pathogen-specific CTL therapy Ceased AU660422B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US578828 1984-02-10
US57882890A 1990-09-06 1990-09-06
PCT/US1991/006441 WO1992004462A1 (en) 1990-09-06 1991-09-06 Pathogen-specific ctl therapy
CA002089488A CA2089488A1 (en) 1990-09-06 1991-09-06 Pathogen-specific ctl therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU17725/95A Division AU682256B2 (en) 1990-09-06 1995-04-28 Pathogen-specific CTL therapy

Publications (2)

Publication Number Publication Date
AU8737991A AU8737991A (en) 1992-03-30
AU660422B2 true AU660422B2 (en) 1995-06-29

Family

ID=25675897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87379/91A Ceased AU660422B2 (en) 1990-09-06 1991-09-06 Pathogen-specific CTL therapy

Country Status (4)

Country Link
EP (1) EP0547166A1 (online.php)
AU (1) AU660422B2 (online.php)
CA (1) CA2089488A1 (online.php)
WO (1) WO1992004462A1 (online.php)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
WO1992021377A1 (en) * 1991-06-03 1992-12-10 Syntello Inc. Peptides for use in induction of t cell activation against hiv-1
ES2313719T3 (es) 1993-11-23 2009-03-01 The Regents Of The University Of California Productos extracelulares abundantes y procedimiento de produccion y uso de los mismos.
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
JPH11511968A (ja) * 1995-08-21 1999-10-19 デューク ユニバーシティ 抗原提示細胞上にて抗原密度を増加させる方法
US5994308A (en) * 1996-02-28 1999-11-30 Board Of Trustees Of Southern Illinois University Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
DE19710496A1 (de) * 1997-03-13 1998-09-17 Boehringer Mannheim Gmbh Verfahren zum Nachweis antigenspezifischer T-Zellen nach Anreicherung von mononukleären Zellpopulationen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107861T1 (de) * 1986-09-19 1994-07-15 Oncogen Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
169 PP1421-1434 *
PP 459-470; TSUBOTA, H ET AL (1989) JOUR. EXP. MEDICINE VOL *
WATANA, E ET AL (1987) JOURN EXP. MEDICINE V 133 (NO.1) *

Also Published As

Publication number Publication date
WO1992004462A1 (en) 1992-03-19
AU8737991A (en) 1992-03-30
CA2089488A1 (en) 1993-03-07
EP0547166A1 (en) 1993-06-23
EP0547166A4 (online.php) 1994-03-09

Similar Documents

Publication Publication Date Title
Castro et al. Suppression of human immunodeficiency virus replication by CD8+ cells from infected and uninfected chimpanzees
Yasutomi et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys
Moris et al. Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer
Kanai et al. IL-15 stimulates the expansion of AIDS virus-specific CTL
Perez et al. An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation
Shen et al. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes
US5081029A (en) Methods of adoptive immunotherapy for treatment of aids
Jacobson et al. HTLV‐I‐specific cytotoxic T lymphocytes in the cerebrospinal fluid of patients with HTLV‐I‐associated neurological disease
Keefer et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59
Yasutomi et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge
DE69420034T2 (de) Synthetische mischpeptide, die die entstehung von neutralisierenden antikörpern und die wirkung der cytotoxischen t-lymphozyten gegen hiv hervorufen
Dai et al. Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes
Chehimi et al. In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates
Klarnet et al. FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.
WO1989005349A1 (en) Method of combating viral infections
JP2020513782A (ja) Ｈｉｖ感染を治療するキメラ抗原受容体の組換え遺伝子構築およびその応用
Yasutomi et al. Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys.
Littaua et al. A CD4+ cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6
Takahashi et al. Specific lysis of human immunodeficiency virus type 1-infected cells by a HLA-A3. 1-restricted CD8+ cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein.
AU769538B2 (en) Efficient ex vivo expansion of CD4+ and CD8+ T-cells from HIV infected subjects
AU8737991A (en) Pathogen-specific ctl therapy
WO1993014789A1 (en) Pathogen-specific ctl therapy
CA2265885A1 (en) Pharmaceutical compositions for the treatment of immune disorders
De Maria et al. CD8+ cytolytic T lymphocytes become infected in vitro in the process of killing HIV‐1‐infected target cells
Lee et al. Cytotoxic activity against maedi-visna virus-infected macrophages